GLP-1s vs peptides: what's the difference?

The word 'peptide' is being used as a catch-all marketing label for everything from FDA-approved GLP-1 receptor agonists like semaglutide and tirzepatide to a long tail of research-grade compounds sold online with vague claims.

Both categories overlap chemically — GLP-1s are technically peptides — but they live in completely different regulatory worlds. That difference is the whole story for safety, legality, and what your clinician can actually prescribe.

If you've spent an hour scrolling TikTok or reading Reddit threads on this, you've probably seen the same product framed as 'a miracle weight-loss peptide', 'a gray-market research compound', and 'basically the same thing as Ozempic' — sometimes in three adjacent posts. Those framings aren't all wrong. They're describing different slices of the same word.

The goal of this piece is not to tell you which slice is right for you. It's to give you a vocabulary precise enough that a clinician, a pharmacist, or a thoughtful skeptic can have a real conversation with you about what you're actually considering.

GLP-1 (glucagon-like peptide-1) is a hormone your body already produces. GLP-1 receptor agonists are medications designed to mimic that hormone and slow gastric emptying, blunt appetite, and improve glycemic control.

The most discussed examples are semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), which is technically a GLP-1/GIP dual agonist. These are FDA-approved drugs with published trial data, defined indications, and regulated manufacturing.

What 'FDA-approved' actually buys you, in plain terms: a specific molecule, made to a specified purity, in a specified dose, packaged in a specified delivery device, with a specified label of what it's for and what to watch out for. Years of trial data sit behind every one of those specifications. None of that exists by accident, and none of it transfers automatically to a product that looks similar.

These drugs were originally developed for type 2 diabetes. The weight-loss indications (Wegovy, Zepbound) came later, on the strength of trials specifically designed to measure weight outcomes. That's why the same molecule can be 'approved' for one use and 'off-label' for another — the approval attaches to the specific use, not the molecule in the abstract.

When you see 'peptide therapy' marketed online — especially anything sold as a powder for reconstitution, or labeled 'research only' — you are usually looking at compounds that are not FDA-approved for the use being implied.

Some are compounded versions of FDA-approved drugs prepared by 503A or 503B pharmacies. Others are research chemicals with no clinical-grade oversight at all. The visual packaging often looks identical. The legal and safety footing is not.

A useful mental sort: ask whether the product is (a) an FDA-approved drug from a licensed pharmacy, (b) a compounded version of an FDA-approved drug from a US compounding pharmacy with a prescription, (c) a 'research chemical' sold without a prescription, or (d) something imported from overseas with no US oversight at all. Those are four very different products even when the molecule on the label is the same word.

Marketing copy almost never makes this sort for you. The phrase 'pharmaceutical grade' is not a regulatory category. 'Made in a licensed facility' tells you nothing about what was made. 'Used by clinicians' is not a substitute for a prescription written for you, by a clinician who has evaluated you.

Compounded GLP-1s — semaglutide or tirzepatide prepared by a US compounding pharmacy — sit in a real but narrow legal lane. Historically that lane widened when the FDA listed the branded drug as in shortage, which temporarily allowed compounders to prepare 'essentially copies'. As supply normalizes, the FDA has been clarifying when that's still permitted.

This matters to you for one practical reason: a clinic's offering may be legal this quarter and not the next, without anything visibly changing on the website. If you're considering compounded, it's reasonable to ask the prescriber, in writing, what their plan is when the relevant FDA shortage listing ends.

When you ask 'is this peptide safe?', the honest answer depends on which bucket you're talking about: an FDA-approved injectable from a licensed pharmacy, a compounded version of that drug, or an unregulated research compound. Each has different evidence, oversight, and risk.

Throughout this site we try to be explicit about which bucket we're discussing rather than collapsing them into one word.

The same applies to efficacy. A trial result for branded semaglutide is a trial result for that specific formulation, at that specific dose, in that specific population. It is suggestive — not definitive — for a compounded version with a different fill volume and different additives, and it tells you essentially nothing about an unregulated research compound sold under the same chemical name.

Bring the specific product name and source. 'I'm considering compounded semaglutide from Pharmacy X, prescribed through Clinic Y' is a workable starting point. 'I want to try peptides' is not — your clinician has no way to evaluate that.

Ask which bucket your clinician is comfortable prescribing from, and why. A clinician who will only prescribe branded products is making a specific risk decision. So is one who routinely prescribes compounded. Neither is automatically wrong, but the reasoning should be explicit.

If you're already taking something you bought online without a prescription, tell your clinician anyway. The visit is more useful when they know what's actually in your body than when they're answering a hypothetical.

GLP-1 receptor agonist — a drug that mimics the GLP-1 hormone. Semaglutide and tirzepatide are the most common examples.

Branded GLP-1 — an FDA-approved product from the original manufacturer (e.g. Ozempic, Wegovy, Mounjaro, Zepbound).

Compounded GLP-1 — a version prepared by a US compounding pharmacy under a prescription, in a legal lane that's narrowing as supply normalizes.

503A pharmacy — compounds individual prescriptions; lighter FDA oversight, no FDA approval of the product itself.

503B outsourcing facility — produces larger batches under stricter FDA oversight; still not the same as an FDA-approved drug.

Research peptide — a compound sold for laboratory use, not human use; not a regulatory shortcut to a prescription drug.